Atlas Venture Opportunity Fund I, L.P.'s Net Worth

$471 Million

Estimate Recalculated Feb 28, 2024 07:58PM EST

Who is Atlas Venture Opportunity Fund I, L.P.?

Atlas Venture Opportunity Fund I, L.P. has an estimated net worth of $471 Million. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., and Third Harmonic Bio, Inc..

SEC CIK

Atlas Venture Opportunity Fund I, L.P.'s CIK is 0001759241

Past Insider Trading and Trends

2021 was Atlas Venture Opportunity Fund I, L.P.'s most active year for acquiring shares with 13 total transactions. Atlas Venture Opportunity Fund I, L.P.'s most active month to acquire stocks was the month of May. 2021 was Atlas Venture Opportunity Fund I, L.P.'s most active year for disposing of shares, totalling 33 transactions. Atlas Venture Opportunity Fund I, L.P.'s most active month to dispose stocks was the month of November. 2022 saw Atlas Venture Opportunity Fund I, L.P. paying a total of $34,090,021.70 for 16,180,239 shares, this is the most they've acquired in one year. In 2023 Atlas Venture Opportunity Fund I, L.P. cashed out on 675,637 shares for a total of $34,351,525.03, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $15.51

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-20.00%
-198.28K
793.12K
Scheduled
Jul 1
Form 4
766.67K
$15.00
$11,500,005.00
766.67K
Jun 17
Form 4
9M
$16.00
$8,000,000.00
9M
Feb 1 - Jun 1
Form 3
0
0
No matching records found

Dyne Therapeutics, Inc. (DYN) Snapshot price: $21.54

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-5.89%
-807.84K
$24.32
-$19,626,902.97
12.9M
Scheduled
Feb 26 - Feb 28
Form 4
-5.35%
-500.79K
$22.68
-$11,339,780.44
8.86M
Scheduled
Feb 21 - Feb 23
Form 4
934.58K
$10.70
$10,000,016.70
934.58K
Dec 12
Form 4
+361.95%
7.64M
9.75M
Sep 21
Form 3
0
0
No matching records found

Akero Therapeutics, Inc. (AKRO) Snapshot price: $17.66

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.11%
-50.51K
404.08K
Scheduled
Feb 7
Form 4
-14.36%
-570.97K
3.4M
Scheduled
Dec 17
Form 4
3.97M
$16.00
3.97M
Jun 24
Form 3
0
0
No matching records found

Ikena Oncology, Inc. (IKNA) Snapshot price: $1.385

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4.89%
98.72K
$15.34
$1,614,428.13
2.12M
Mar 30 - Dec 14
Form 4
+2,809.29%
4.75M
4.92M
Mar 30
Form 3
0
0
No matching records found

Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.6382

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-0.04%
-1.00K
$0.64
-$640.00
2.75M
Feb 8
Form 4
-0.15%
-4.24K
$0.85
-$3,600.45
2.76M
Jan 11 - Jan 12
Form 4
+10,385.82%
2.73M
$16.00
2.76M
Oct 26
Form 3
0
0
No matching records found